FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979945145> ?p ?o ?g. }

• W2979945145 abstract "Abstract Combination of Imatinib with chemotherapy has been reported as very promising for patients with Ph+ ALL. In this study, we attempted to minimize the MRD (Minimal Residual Disease) level before transplant for Ph+ ALL by combining Imatinib with HAM (HAMI). This regimen consisted to Cytarabine 2g/m2/12 hours between day1 and day4, Mitoxantrone 10mg/m2/day between day1 and day3 combinated with Imatinib (3 different doses) between day1 and day45. MRD was studied by RT-PCR at day1 (before treatment) and day45 (after treatment) and was exprimed by BCR-ABL/ABL levels. Between April 2002 and September 2005, 36 patients in complete remission (CR) after induction chemotherapy have been analysed. This group consisted of 13 females and 23 males with a median age of 42 years (19–60). Three doses of Imatinib (400 mg, 600 mg and 800 mg/day) have been tested for six patients in each cohort (the first eighteen patients). After an intermediate analysis, the dose of 800 mg per day has been shown to be toxic (one grade IV hypokaliemia), and a last cohort of 18 patients were treated with 600 mg/day. No toxic-death related to HAMI regimen was reported. Thirthy-one patients could be studied for MRD before and after HAMI consolidation. Four patients were in molecular remission (level of BCR-ABL/ABL<10−5) before treatment and 12 after. No difference between 3 cohorts of dose was observed. The median level of MRD was 10−3 (0–0.7) and 3 × 10−5 (0–0.004) before and after treatment respectively (p=0.0015). After a median follow-up of two years and for all patients, the estimated overall survival (OS) and disease free survival were respectively of 71% (51%–84%) and 52% (32%–69%). The cumulative incidence of relapse and the cumulative incidence of death in CR were respectively of 15% (6%–32%) and 31% (17%–52%). Twenty patients had allogenic matched transplantation (thirteen related, seven unrelated) and composed the group with donor. In this first group, seven patients obtained MRD negativity after HAMI treatment. The others sixteen patients composed the second group of patients without donor or older than 55 years. In this second group, eleven patients received autologous stem-cell transplant followed by imatinib for nine of them, and five received imatinib in maintenance with or without chemotherapy. In this group, six patients had obtained MRD negativity after HAMI. The two-years OS was identical for patients with or without donor (71%). In conclusion, imatinib combined with high dose chemotherapy improved molecular remission before transplantation and lead to an improve outcome." @default.
• W2979945145 created "2019-10-18" @default.
• W2979945145 creator A5000074573 @default.
• W2979945145 creator A5000436961 @default.
• W2979945145 creator A5003572390 @default.
• W2979945145 creator A5012805294 @default.
• W2979945145 creator A5017435311 @default.
• W2979945145 creator A5018416096 @default.
• W2979945145 creator A5030574503 @default.
• W2979945145 creator A5035348501 @default.
• W2979945145 creator A5037324033 @default.
• W2979945145 creator A5039996784 @default.
• W2979945145 creator A5043286121 @default.
• W2979945145 creator A5046436694 @default.
• W2979945145 creator A5069084023 @default.
• W2979945145 creator A5071962621 @default.
• W2979945145 creator A5072721892 @default.
• W2979945145 date "2006-11-16" @default.
• W2979945145 modified "2023-09-27" @default.
• W2979945145 title "Post-Remission Therapy with Imatinib and HAM Improve MRD before Tansplant for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL): Results of the GRAALL AFR03 Study." @default.
• W2979945145 doi "https://doi.org/10.1182/blood.v108.11.1877.1877" @default.
• W2979945145 hasPublicationYear "2006" @default.
• W2979945145 type Work @default.
• W2979945145 sameAs 2979945145 @default.
• W2979945145 citedByCount "0" @default.
• W2979945145 crossrefType "journal-article" @default.
• W2979945145 hasAuthorship W2979945145A5000074573 @default.
• W2979945145 hasAuthorship W2979945145A5000436961 @default.
• W2979945145 hasAuthorship W2979945145A5003572390 @default.
• W2979945145 hasAuthorship W2979945145A5012805294 @default.
• W2979945145 hasAuthorship W2979945145A5017435311 @default.
• W2979945145 hasAuthorship W2979945145A5018416096 @default.
• W2979945145 hasAuthorship W2979945145A5030574503 @default.
• W2979945145 hasAuthorship W2979945145A5035348501 @default.
• W2979945145 hasAuthorship W2979945145A5037324033 @default.
• W2979945145 hasAuthorship W2979945145A5039996784 @default.
• W2979945145 hasAuthorship W2979945145A5043286121 @default.
• W2979945145 hasAuthorship W2979945145A5046436694 @default.
• W2979945145 hasAuthorship W2979945145A5069084023 @default.
• W2979945145 hasAuthorship W2979945145A5071962621 @default.
• W2979945145 hasAuthorship W2979945145A5072721892 @default.
• W2979945145 hasConcept C126322002 @default.
• W2979945145 hasConcept C141071460 @default.
• W2979945145 hasConcept C2776694085 @default.
• W2979945145 hasConcept C2777583451 @default.
• W2979945145 hasConcept C2778041864 @default.
• W2979945145 hasConcept C2778461978 @default.
• W2979945145 hasConcept C2778729363 @default.
• W2979945145 hasConcept C2779823535 @default.
• W2979945145 hasConcept C2780923524 @default.
• W2979945145 hasConcept C2781107101 @default.
• W2979945145 hasConcept C2781413609 @default.
• W2979945145 hasConcept C2909962599 @default.
• W2979945145 hasConcept C3019892230 @default.
• W2979945145 hasConcept C71924100 @default.
• W2979945145 hasConcept C72563966 @default.
• W2979945145 hasConcept C90924648 @default.
• W2979945145 hasConceptScore W2979945145C126322002 @default.
• W2979945145 hasConceptScore W2979945145C141071460 @default.
• W2979945145 hasConceptScore W2979945145C2776694085 @default.
• W2979945145 hasConceptScore W2979945145C2777583451 @default.
• W2979945145 hasConceptScore W2979945145C2778041864 @default.
• W2979945145 hasConceptScore W2979945145C2778461978 @default.
• W2979945145 hasConceptScore W2979945145C2778729363 @default.
• W2979945145 hasConceptScore W2979945145C2779823535 @default.
• W2979945145 hasConceptScore W2979945145C2780923524 @default.
• W2979945145 hasConceptScore W2979945145C2781107101 @default.
• W2979945145 hasConceptScore W2979945145C2781413609 @default.
• W2979945145 hasConceptScore W2979945145C2909962599 @default.
• W2979945145 hasConceptScore W2979945145C3019892230 @default.
• W2979945145 hasConceptScore W2979945145C71924100 @default.
• W2979945145 hasConceptScore W2979945145C72563966 @default.
• W2979945145 hasConceptScore W2979945145C90924648 @default.
• W2979945145 hasLocation W29799451451 @default.
• W2979945145 hasOpenAccess W2979945145 @default.
• W2979945145 hasPrimaryLocation W29799451451 @default.
• W2979945145 hasRelatedWork W2000116184 @default.
• W2979945145 hasRelatedWork W2019071187 @default.
• W2979945145 hasRelatedWork W2081238814 @default.
• W2979945145 hasRelatedWork W2133433269 @default.
• W2979945145 hasRelatedWork W2537976142 @default.
• W2979945145 hasRelatedWork W2549110367 @default.
• W2979945145 hasRelatedWork W2555721349 @default.
• W2979945145 hasRelatedWork W2563620804 @default.
• W2979945145 hasRelatedWork W2567682233 @default.
• W2979945145 hasRelatedWork W2979945145 @default.
• W2979945145 isParatext "false" @default.
• W2979945145 isRetracted "false" @default.
• W2979945145 magId "2979945145" @default.
• W2979945145 workType "article" @default.